RE:RE:RE:More comments on Biogen's aducanumab I think it means that preferential development of anti-amyloid would occur, which would be good for PMN, actually. For non-amyloid approaches, he is saying it would be a setback.
This seems consistent with messaging from management that investors are sitting on the sidelines until the FDA confirms a winning approach.